Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care
Six entrepreneurs presented compelling pitches about their investment-ready companies and technologies to an audience of health care experts, providers, and investors. Not only did the pitches showcase the latest thinking in digital and patient engagement approaches, U.S. Psych Congress awarded the winner $5,000 to support the ongoing development of their technology platform.
“At Otsuka, we are proud of our commitment to developing innovative solutions. At the heart of this work is addressing mental health disorders and supporting patients and caregivers,” said Andrew Wright, vice president of Digital Medicine for Otsuka. “We are thrilled to support this Pitch Event and Elevate by Psych Congress. By convening some of the best entrepreneurs in technology and mental health, and giving them an opportunity to engage directly with the leading experts in the field, we can spark new conversations and road-test new ideas.”
The pitch companies showcased technologies that address unmet needs in the mental health community. These included technologies that impact medication adherence, solutions that address mental health literacy and the need for understanding side effects and medication regimes, innovations that address early detection and the promotion of wellness and services that have bridged the gap in education and self-advocacy.
The winner of the 2018 Pitch Event at Elevate by Psych Congress was NeuroFlow, a Philadelphia-based and veteran-founded creator of technology to supports individuals with mental illness. Through the capture of real-time and secure patient-generated data, including biometrics, questionnaires and journaling, NeuroFlow’s technology platform supports patients with their treatments via monitoring, positive reinforcement, and targeted guidance. By helping to improve treatment retention and protocol adherence, NeuroFlow promotes better health outcomes for patients and business growth for providers. They are fully launching their platform the first week of March after a successful beta phase with over two-dozen clinics around the country that specialize in CBT, mindfulness and exposure therapies.
“The support of Otsuka and Psych Congress is exciting to everyone at NeuroFlow,” said Christopher Molaro, CEO, and Co-Founder of NeuroFlow. “The fact Psych Congress attendees chose NeuroFlow is validation to the value of our technology and to our belief that technology can play an important role in understanding and supporting those with mental illness and thank Otsuka for their support in that journey.”
Otsuka is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka Pharmaceutical Development & Commercialization, Inc. is an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately US $11 billion in 2016.
All Otsuka stories start by taking the road less traveled. Learn more at https://www.otsuka.co.jp/en.
NeuroFlow helps mental health patients feel better faster. We offer secure, real-time technology that optimizes mental wellness and performance through effective monitoring, positive reinforcement, and targeted guidance.
We enhance and accelerate engagement by demonstrating tangible progress through patient-generated data including biometrics, questionnaires, and journaling. By improving retention and protocol adherence, we promote better health outcomes for patients and business growth for providers. Learn more at http://www.neuroflowsolution.com.
Otsuka America Pharmaceutical, Inc.
Source: Otsuka America Pharmaceutical, Inc.